Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway

Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation. We hypothesized that pre-treatment of glioblastoma with bortezomib (BTZ) mig...

Full description

Bibliographic Details
Published in:	Frontiers in Cell and Developmental Biology
Main Authors:	Mohummad Aminur Rahman, Agnete S. T. Engelsen, Shahin Sarowar, Christian Bindesbøll, Even Birkeland, Dorota Goplen, Maria L. Lotsberg, Stian Knappskog, Anne Simonsen, Martha Chekenya
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Subjects:	glioblastoma (GBM) proteasome inhibitor bortezomib secretome temozolomide chemotherapy cell cycle kinetics autophagy flux
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2022.1022191/full

Similar Items

Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
by: Mohummad A. Rahman, et al.
Published: (2020-09-01)

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
by: Dong Liang, et al.
Published: (2024-09-01)

Combination of First Generation Proteasome Inhibitor Bortezomib with Temozolomide and Radiotherapy in Glioblastoma 2D and 3D Cell Cultures
by: Sema Arslan, et al.
Published: (2018-12-01)

Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
by: Jun-Hai Tang, et al.
Published: (2019-12-01)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
by: Jianhao Liu, et al.
Published: (2021-12-01)

Why bortezomib cannot go with ‘green’?
by: Li Jia, et al.
Published: (2013-12-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Bortezomib-Based Regimens and Plasma Cell Leukemia
by: Ali Zahit Bolaman
Published: (2021-02-01)

Cutaneous Drug Reaction Due to Bortezomib Characterized by Erythematous Reticular Plaques in a Patient With Multiple Myeloma
by: Emre Güven, et al.
Published: (2024-10-01)

Effective response with bortezomib retreatment in relapsed multiple myeloma
by: Christian Taverna, et al.
Published: (2012-04-01)

Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
by: Sinan Mersin, et al.
Published: (2021-08-01)

Mechanisms and Pathophysiological Roles of the ATG8 Conjugation Machinery
by: Alf Håkon Lystad, et al.
Published: (2019-08-01)

Goshajinkigan reduces bortezomib-induced mechanical allodynia in rats: Possible involvement of kappa opioid receptor
by: Hitomi Higuchi, et al.
Published: (2015-11-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
by: Fabiana Gentilini, et al.
Published: (2012-01-01)

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
by: Fabiana Gentilini, et al.
Published: (2012-05-01)

A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
by: Soo-Young Bae, et al.
Published: (2011-02-01)

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
by: Ye Z, et al.
Published: (2019-05-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Experimental Study on the Mechanism of Reversal of Leukemia Multidrug Resistance by Proteasome Inhibitor Bortezomib
by: Ying-chun LI, et al.
Published: (2010-08-01)

Cost-Effectiveness of Rituximab Versus Bortezomib in Kidney Transplant Patients
by: Yadgar Rashidi, et al.
Published: (2024-05-01)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
by: T.B.M. Castro, et al.
Published: (2016-01-01)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
by: T.B.M. Castro, et al.
Published: (2016-05-01)

Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia
by: Elif Suyanı, et al.
Published: (2012-08-01)

Bortezomib in the management of anti-NMDA receptor encephalitis
by: Bryan Gervais de Liyis, et al.
Published: (2023-12-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

ID221 Bortezomib for the treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis
by: Vania dos Santos Nunes Nogueira, et al.
Published: (2024-11-01)

Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition
by: Duen-Ren Hou, et al.
Published: (2013-12-01)

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine
by: India and Ukraine Haemato-oncology Group, et al.
Published: (2016-11-01)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
by: Joseph Han, et al.
Published: (2023-07-01)

Administração subcutânea de bortezomib: uma nova realidade no tratamento de doentes com mieloma múltiplo
by: Rui Santos
Published: (2013-11-01)

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy
by: Charles Yun, et al.
Published: (2015-06-01)

Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats
by: Shota Yamamoto, et al.
Published: (2015-09-01)

The Anti-Tumor and Bortezomib-Sensitizing Effects of Apigenin in Multiple Myeloma
by: Ye Chen, et al.
Published: (2025-09-01)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
by: Chi Zhang, et al.
Published: (2023-11-01)

Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib
by: Jack Fitzsimons, et al.
Published: (2024-06-01)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
by: Esther A. Zaal, et al.
Published: (2017-08-01)